A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
Phase 3
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- First Posted Date
- 2003-01-07
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00051155
- Locations
- 🇺🇸
Europe, Fort Worth, Texas, United States
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
Phase 3
Completed
- Conditions
- Glaucoma, Angle-ClosureOcular Hypertension
- First Posted Date
- 2003-01-07
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00051181
- Locations
- 🇺🇸
Asia, Fort Worth, Texas, United States
🇦🇺Australia, Sidney, Australia
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Phase 3
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- First Posted Date
- 2003-01-07
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00051142
- Locations
- 🇺🇸
Latin America, Fort Worth, Texas, United States
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- First Posted Date
- 2002-10-18
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00047515
- Locations
- 🇺🇸
Clinical Trial Sites, Multiple Locations Throughout the United States, Texas, United States
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
Terminated
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Interventions
- Drug: Travoprost, 0.004% ophthalmic solution
- First Posted Date
- 2002-10-18
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 336
- Registration Number
- NCT00047554
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- First Posted Date
- 2002-10-18
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00047528
- Locations
- 🇺🇸
Clinical Trial Sites, Fort Worth, Texas, United States
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- First Posted Date
- 2002-10-18
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00047541
- Locations
- 🇺🇸
Clinical Trial Sites, Fort Worth, Texas, United States
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
Phase 4
Terminated
- Conditions
- Open-angle GlaucomaOcular Hypertension
- First Posted Date
- 2002-10-11
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 84
- Registration Number
- NCT00047606
Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- First Posted Date
- 2002-10-11
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00047593
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Phase 3
Completed
- Conditions
- Macular Degeneration
- Interventions
- Other: Photodynamic Therapy (PDT)
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 530
- Registration Number
- NCT00041483
- Locations
- 🇺🇸
Contact Alcon Call Center for Trial Locations, Ft. Worth, Texas, United States